Low-Dose Decitabine Modulates Myeloid-Derived Suppressor Cell Fitness via LKB1 in Immune Thrombocytopenia

The authors analyzed the effects of decitabine on myeloid-derived suppressor cells (MDSCs) from patients with immune thrombocytopenia, both in vitro and in vivo, and found that low-dose decitabine promoted the generation of MDSCs, and enhanced their aerobic metabolism and immunosuppressive functions.